DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on October 31, 2017, reports the cash position of DBV Technologies S.A. as of September 30, 2017. DBV Technologies is a biopharmaceutical company developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The company is headquartered in Montrouge, France, with additional operations in New York, NY.
Key Financial Metrics
| Metric | Value |
|---|---|
| Cash and Cash Equivalents (Sept 30, 2017) | €170.5 million |
| Cash and Cash Equivalents (Dec 31, 2016) | €256.5 million |
| Outstanding Shares (Sept 30, 2017) | 24,979,321 |
| Fully Diluted Shares (Sept 30, 2017) | 27,686,521 |
The filing does not provide specific values for revenue, profit, operating cash flow, margins, or debt levels for the period.
Material Changes
Cash and cash equivalents decreased by €86.0 million, representing a decline from €256.5 million as of December 31, 2016, to €170.5 million as of September 30, 2017. The filing does not explicitly detail the specific operational or capital expenditure drivers for this reduction.
Outlook, Risks, and Management Commentary
Management highlights ongoing clinical trials for Viaskin Peanut and Viaskin Milk, as well as preclinical development for Viaskin Egg. The company is also pursuing a human proof-of-concept study for Viaskin Milk to treat Eosinophilic Esophagitis and exploring applications in vaccines. The filing notes that there are currently no approved treatments for food allergies, positioning DBV's non-invasive, self-administered candidates as a potential market transformation. No specific forward-looking financial guidance or quantified risk factors are included in this specific press release.
Investor Verification Checklist
- Verify the specific burn rate and cash runway based on the €86.0 million cash decline over the nine-month period.
- Confirm the status and enrollment numbers of the ongoing Viaskin Peanut and Viaskin Milk clinical trials.
- Review the company's most recent Form 20-F for detailed revenue, expense, and debt information not present in this 6-K.
- Assess the dilution impact of the difference between outstanding shares (24.98M) and fully diluted shares (27.69M).